Diagnostic value of urine deoxypyridinoline for detecting bone metastases in breast cancer patients.

Abstract

Deoxypyridinoline (Dpd), a crosslink product of collagen molecules found in bone and excreted in urine during bone degradation, has been described as a marker of bone turnover in metastatic breast cancer. In this study, the urine deoxypyridinoline/creatinine (Dpd/Cre) ratio was determined by enzyme immunoassay in urine samples from 116 women with breast cancer. Bone metastases were confirmed by x-ray or CT scan, with follow-up > 6 mo. The urine Dpd/Cre ratio was significantly higher in patients with bone metastasis, compared to those without bone metastasis (p < 0.05). In patients with bone metastasis, ratios of urine Dpd/Cre were higher in those with multiple lesions, compared to those with a solitary lesion, and the values also reflected therapeutic response (p < 0.05). Serial monitoring of urine Dpd/Cre revealed that an elevation was correlated with disease progression. Patients with stable bone disease under effective therapy had significant diminution of the urine Dpd/Cre ratios, compared to those with progression of bone disease (p < 0.05). In conclusion, the urine Dpd/Cre ratio may be a useful marker for detecting bone metastases and evaluating their response to therapy.

• Authors: Ming-Feng Hou, Shwu-Bin Lin, Shyng-Shiou F Yuan, Li-Yu Tsai, Shih-Meng Tsai, Jan-Shih Hsieh, Tsung-Jen Huang
• Journal: Annals of clinical and laboratory science (Ann Clin Lab Sci) Vol. 33 Issue 1 Pg. 55-61 ( 2003) ISSN: 0091-7370 [Print] United States
• PMID: 12661898 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Amino Acids
• Biomarkers, Tumor
• Diphosphonates
• deoxypyridinoline

Topics

• Adult
• Aged
• Amino Acids (urine)
• Biomarkers, Tumor (urine)
• Bone Neoplasms (drug therapy, secondary)
• Breast Neoplasms (pathology)
• Diphosphonates (therapeutic use)
• Female
• Humans
• Middle Aged
• Predictive Value of Tests
• Quality Control